Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

319 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.
Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix S, Henley A, Di-Stefano F, Ahmad Z, Guillard S, Bjerke LM, Kelland L, Valenti M, Patterson L, Gowan S, de Haven Brandon A, Hayakawa M, Kaizawa H, Koizumi T, Ohishi T, Patel S, Saghir N, Parker P, Waterfield M, Workman P. Raynaud FI, et al. Among authors: waterfield m. Cancer Res. 2007 Jun 15;67(12):5840-50. doi: 10.1158/0008-5472.CAN-06-4615. Cancer Res. 2007. PMID: 17575152 Free article.
Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
Maloney A, Clarke PA, Naaby-Hansen S, Stein R, Koopman JO, Akpan A, Yang A, Zvelebil M, Cramer R, Stimson L, Aherne W, Banerji U, Judson I, Sharp S, Powers M, deBilly E, Salmons J, Walton M, Burlingame A, Waterfield M, Workman P. Maloney A, et al. Among authors: waterfield m. Cancer Res. 2007 Apr 1;67(7):3239-53. doi: 10.1158/0008-5472.CAN-06-2968. Cancer Res. 2007. PMID: 17409432
Phosphatidylinositol 3-kinase: a novel effector.
Parker PJ, Waterfield MD. Parker PJ, et al. Among authors: waterfield md. Cell Growth Differ. 1992 Oct;3(10):747-52. Cell Growth Differ. 1992. PMID: 1332743 Review. No abstract available.
Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors.
Hayakawa M, Kaizawa H, Moritomo H, Koizumi T, Ohishi T, Yamano M, Okada M, Ohta M, Tsukamoto S, Raynaud FI, Workman P, Waterfield MD, Parker P. Hayakawa M, et al. Among authors: waterfield md. Bioorg Med Chem Lett. 2007 May 1;17(9):2438-42. doi: 10.1016/j.bmcl.2007.02.032. Epub 2007 Feb 15. Bioorg Med Chem Lett. 2007. PMID: 17339109
Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors.
Hayakawa M, Kawaguchi K, Kaizawa H, Koizumi T, Ohishi T, Yamano M, Okada M, Ohta M, Tsukamoto S, Raynaud FI, Parker P, Workman P, Waterfield MD. Hayakawa M, et al. Among authors: waterfield md. Bioorg Med Chem. 2007 Sep 1;15(17):5837-44. doi: 10.1016/j.bmc.2007.05.070. Epub 2007 Jun 6. Bioorg Med Chem. 2007. PMID: 17601739
Republication: Targeting PI3KC2β Impairs Proliferation and Survival in Acute Leukemia, Brain Tumours and Neuroendocrine Tumours.
Boller D, Doepfner KT, Laurentiis A, Guerreiro AS, Marinov M, Shalaby T, Depledge P, Robson A, Saghir N, Hayakawa M, Kaizawa H, Koizumi T, Ohishi T, Fattet S, Delattre O, Schweri-Olac A, Höland K, Grotzer MA, Frei K, Spertini O, Waterfield MD, Arcaro A. Boller D, et al. Among authors: waterfield md. Anticancer Res. 2022 Jun;42(6):3217-3230. doi: 10.21873/anticanres.15812. Anticancer Res. 2022. PMID: 35641277 Free article.
319 results